
Henry Schein (HSIC) Stock Forecast & Price Target
Henry Schein (HSIC) Analyst Ratings
Bulls say
Henry Schein Inc. demonstrated a solid performance with multiple segments showing growth, particularly in the Global Technology segment, which generated $173 million in revenue with a growth rate of 9.7% as reported. Additionally, the medical products revenue exhibited a strong increase of 6.3% as reported, indicating robust demand in that sector. Furthermore, the anticipated mid-single-digit growth in adjusted EBITDA for FY 2025 reinforces a positive outlook for the company's financial health and operational efficiency.
Bears say
Henry Schein Inc's recent financial performance delivered disappointing results, particularly in profitability, with gross margins reported at 31.4%, falling short of expectations by 110 basis points. Furthermore, the company's revenue trajectory revealed challenges, with US dental merchandise revenue declining by 1.2% amidst pricing pressure, while international revenues faced a similar decline when adjusted for local currencies. The outlook for adjusted EBITDA has also been revised downward, now projected at $1.090 billion for FY/25, reflecting a continued concern about the company's ability to maintain profitability amidst these headwinds.
This aggregate rating is based on analysts' research of Henry Schein and is not a guaranteed prediction by Public.com or investment advice.
Henry Schein (HSIC) Analyst Forecast & Price Prediction
Start investing in Henry Schein (HSIC)
Order type
Buy in
Order amount
Est. shares
0 shares